[Serologic follow-up of cytomegalovirus, herpes simplex and varicella-zoster infections in kidney transplant recipients].
In the present paper the characteristics of cytomegalovirus (CMV), herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections were serologically investigated in renal transplant recipients. At transplantation CMV-seropositivity was 88.2%. At the end of the study, the frequency of primary CMV-infections was 58.3% and the frequency of recurrent infections (reinfections or reactivations) was 84.4%. The 57.1% of primary infections and the 64.5% of recurrent infections occurred between the first and the third month after transplantation. There was no correlation between recurrent infections and type of immunosuppressive treatment (CyA vs. Triple). The 70% of pairs of patients who received a kidney from the same CMV-seropositive donor reacted in the same way: or neither had any infection or both had active CMV-infection. There was no correlation between rejection and active CMV-infection. HSV-seropositivity was 96.2%. Primary HSV-infections didn't occur and the frequency of reactivation in seropositive patients was 31.4%. No correlation was found between rejection and active HSV-infection as well. As regards VZV-infection, seropositivity at transplantation was 90%. Primary VZV-infections didn't occur. During the study, seropositive patients showed variations in VZV-antibody titers which returned to initial values. Clinical signs of zoster were observed in 6% of patients at third and ninth month after transplantation and were serologically confirmed.
Merlino
C
C
Istituto di Microbiologia, Università di Torino.
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D003587:Cytomegalovirus / Q000254:growth & development / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000453:epidemiology / Q000276:immunology* / Q000635:transmission; D005500:Follow-Up Studies; D006084:Graft Rejection; D006561:Herpes Simplex / Q000453:epidemiology / Q000276:immunology* / Q000635:transmission; D006562:Herpes Zoster / Q000453:epidemiology / Q000276:immunology* / Q000635:transmission; D014645:Herpesvirus 3, Human / Q000254:growth & development / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007075:Immunoglobulin M / Q000276:immunology; D007165:Immunosuppression Therapy / Q000009:adverse effects; D015994:Incidence; D016030:Kidney Transplantation / Q000009:adverse effects; D008875:Middle Aged; D012008:Recurrence; D018139:Simplexvirus / Q000254:growth & development / Q000276:immunology; D014775:Virus Activation
D000914:Antibodies, Viral; D007074:Immunoglobulin G; D007075:Immunoglobulin M
Controllo sierologico delle infezioni da citomegalovirus, herpes simplex e varicella-zoster virus nei portatori di trapianto renale.